Granules India Limited has announced positive regulatory news from its US operations, with the company's subsidiary Granules Consumer Health, LLC receiving a favorable FDA inspection report with No Action Indicated status.

FDA Inspection Results

Granules Consumer Health, LLC, a wholly-owned subsidiary of Granules Pharmaceuticals, Inc., has received an Establishment Inspection Report (EIR) with No Action Indicated (NAI) Status from the US Food and Drug Administration. The FDA inspection was conducted at the company's packaging facility in Manassas, Virginia, from December 1 to 3, 2025.

Facility Operations and Significance

The inspected facility holds significant importance within Granules India's US operations structure. Granules Consumer Health serves as the company's front-end division for OTC products in the US, processing controlled substances and over-the-counter products across three advanced packaging lines. The facility is responsible for packaging both OTC and prescription products and serves as a distribution hub for OTC products across the US market.

Management Commentary

Dr. Krishna Prasad Chigurupati, Chairman and Managing Director of Granules India, commented on the achievement: "Granules Consumer Health plays a critical role in our global operations as a packaging and distribution site. We process controlled substances and over-the-counter (OTC) products across three advanced packaging lines. Achieving zero observations in this inspection reflects the strong culture of quality, safety and regulatory excellence demonstrated by our teams."

Regulatory Compliance Track Record

This marks the facility's second consecutive FDA inspection with zero observations, following the March 2023 audit which also concluded with no issues identified. The successful completion of the FDA inspection with No Action Indicated status reflects the subsidiary's commitment to maintaining high operational standards and validates the facility's adherence to FDA regulations governing pharmaceutical packaging and distribution operations.

Granules India Limited has successfully completed a significant preferential allotment of securities, marking a substantial capital raising exercise. The Share Transfer and Stakeholders Relationship Committee of the Board of Directors approved the allotment on February 23, 2026, following in-principle approvals from stock exchanges received on February 10, 2026.

Convertible Warrants Allotment Details

The company allotted 2,50,00,000 convertible warrants on a preferential basis to members of both promoter group and non-promoter investor categories. These warrants are convertible into an equivalent number of fully paid equity shares with a face value of ₹1 each, priced at ₹585 per warrant.

The warrants can be exercised in one or more tranches within 18 months from the allotment date. Investors have paid 25% of the consideration upfront, amounting to ₹365.625 crores, with the remaining 75% payable upon conversion to equity shares.

Promoter Group Participation

Among the promoter group, Mrs. Chigurupati Uma Devi received the largest allocation of 2,48,80,342 warrants, which will increase her shareholding from 3.81% to 12.51% upon full conversion. Other family members including Mrs. Chigurupati Priyanka, Mrs. Pragnya Chigurupati, and Mr. Harsha Chigurupati also participated in the allotment.

Equity Shares Allotment

Simultaneously, the company allotted 51,28,205 fully paid-up equity shares exclusively to non-promoter category investors at ₹585 per share, raising ₹300 crores. Eight institutional investors from the 360 ONE group participated in this equity allotment.

Impact on Share Capital

Following these allotments, the company's capital structure has been significantly enhanced. The paid-up equity share capital increased from ₹24,26,68,716 to ₹24,77,96,921, representing 24,77,96,921 fully paid-up equity shares of ₹1 each.

On a diluted basis, assuming full conversion of all warrants, the total equity share capital will reach ₹27,27,96,921, comprising 27,27,96,921 fully paid-up equity shares.

Regulatory Compliance and Terms

The preferential allotment was conducted in accordance with Chapter V of SEBI ICDR Regulations and other applicable laws. The securities were issued on a private placement basis, with the issue price determined as per Regulation 164 of the SEBI ICDR Regulations. All allotted equity shares rank pari-passu with existing equity shares of the company. If warrant holders fail to exercise their conversion rights within the stipulated 18-month period, the unexercised warrants will lapse and the 25% consideration paid will be forfeited by the company.